Prevail Therapeutics, a subsidiary of Lilly, has entered into a collaboration with Scribe Therapeutics to leverage the latter’s CRISPR technology to develop in vivo therapies for serious neurological and neuromuscular diseases. The deal will grant Prevail access to Scribe’s X-Editing platform enabled by its CRISPR by Design™ approach in exchange for an upfront payment and equity investment of US$75 M and up to US$1.5 B in milestone payments. The deal marks the third big pharma partnership for Scribe after it signed similarly focused deals with Biogen and Sanofi.